BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 27556823)

  • 1. Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification.
    Brunelli M; Erdini F; Cima L; Eccher A; Fioravanzo A; Gobbo S; Segala D; Ghimenton C; Mazzoleni G; Munari E; Carella R; Martignoni G
    Appl Immunohistochem Mol Morphol; 2018; 26(5):316-323. PubMed ID: 27556823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases.
    Pan CC; Chen PC; Ho DM
    Histopathology; 2004 Nov; 45(5):452-9. PubMed ID: 15500648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.
    Young JR; Coy H; Kim HJ; Douek M; Lo P; Pantuck AJ; Raman SS
    AJR Am J Roentgenol; 2017 Apr; 208(4):812-819. PubMed ID: 28125273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
    Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
    Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma.
    Choi YD; Kim KS; Ryu S; Park Y; Cho NH; Rha SH; Jang JJ; Ro JY; Juhng SW; Choi C
    J Korean Med Sci; 2007 Apr; 22(2):305-10. PubMed ID: 17449941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas.
    Mosquera JM; Dal Cin P; Mertz KD; Perner S; Davis IJ; Fisher DE; Rubin MA; Hirsch MS
    Diagn Mol Pathol; 2011 Sep; 20(3):129-37. PubMed ID: 21817901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.
    Young JR; Margolis D; Sauk S; Pantuck AJ; Sayre J; Raman SS
    Radiology; 2013 May; 267(2):444-53. PubMed ID: 23382290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and clinical significance of kidney injury molecule-1 in renal epithelial neoplasms].
    Dong YC; Wu B; Wang JD; Rao Q; Ma HH; Zhang RS; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):35-9. PubMed ID: 20388397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms.
    Gonzalez-Roibon N; Faraj SF; Munari E; Bezerra SM; Albadine R; Sharma R; Argani P; Allaf ME; Netto GJ
    Hum Pathol; 2014 Feb; 45(2):244-8. PubMed ID: 24315206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms.
    Avery AK; Beckstead J; Renshaw AA; Corless CL
    Am J Surg Pathol; 2000 Feb; 24(2):203-10. PubMed ID: 10680888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic approach to eosinophilic renal neoplasms.
    Kryvenko ON; Jorda M; Argani P; Epstein JI
    Arch Pathol Lab Med; 2014 Nov; 138(11):1531-41. PubMed ID: 25357116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma.
    Adley BP; Papavero V; Sugimura J; Teh BT; Yang XJ
    Anal Quant Cytol Histol; 2006 Aug; 28(4):228-36. PubMed ID: 16927643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma.
    Wang HY; Mills SE
    Am J Surg Pathol; 2005 May; 29(5):640-6. PubMed ID: 15832088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
    Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
    Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different DNA ploidy patterns for the differentiation of common subtypes of renal tumors.
    Li G; Cottier M; Sabido O; Gentil-Perret A; Lambert C; Genin C; Tostain J
    Cell Oncol; 2005; 27(1):51-6. PubMed ID: 15750207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.
    Kuroda N; Guo L; Toi M; Naruse K; Miyazaki E; Hayashi Y; Yoshikawa C; Ashida S; Shuin T; Enzan H
    Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):315-8. PubMed ID: 11759057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
    Alshenawy HA
    Pathol Oncol Res; 2015 Sep; 21(4):893-9. PubMed ID: 25712789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
    Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
    Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the Na+/K+-transporting ATPase gamma subunit FXYD2 in renal tumors.
    Gaut JP; Crimmins DL; Lockwood CM; McQuillan JJ; Ladenson JH
    Mod Pathol; 2013 May; 26(5):716-24. PubMed ID: 23196795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.